glp 1 drugs injection New Guidelines on GLP-1 for Obesity Released The FDA has approved the

Social determinants of health screening is relevant to assess potential barriers to drug access and adherence as well as lifestyle change

Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, et al

In recent years, GLP-1RAs, initially developed for treating T2DM, have gained increasing attention for their cardioprotective effectsparticularly in improving left ventricular function and reducing cardiovascular events

For those with obesity or type 2 diabetes, this number jumps dramatically to over 50% 18

Results show broad benefits with a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimers disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions

Single receptor agonists, liraglutide and semaglutide, were not shown to measurably cross the BBB, implying that these GLP-1 receptor agonists may influence brain function indirectly and act at brain regions outside the BBB [21]